Anticoagulant Reversal Drugs Market, By Type (Prothrombin Complex Concentrates (PCC), Protamine, Vitamin K, Tranexamic Acid, Idarucizumab, AndeXXa, and Others), By Application (Hospital Pharmacies, Retail Pharmacies, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Anticoagulant reversal drugs are used when the anticoagulant drug needs to be reversed the side effect such as bleeding complications, an overdose of the anticoagulant drug, or unplanned surgery. Some of the commercialized anticoagulant reversal drugs include Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa.

The Anticoagulant Reversal Drugs market was valued at 970.6 million US$ in 2022 and is projected to reach 2673 million US$ by 2030, at a CAGR of 13.5% during the forecast period.

Market Dynamics

Increasing regulatory approval for anticoagulant reversal drugs is the major driving factor for the market. For instance, The U.S. Food and Drug Administration (FDA) has approved Andexxa, the first factor Xa inhibitor antidote for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis). Andexxa is used for reversal of anticoagulation due to life-threatening or uncontrolled bleeding. Andexxa has received both U.S. orphan drug and FDA breakthrough therapy designations. The approval of Andexxa is supported by Phase 3 ANNEXA studies, which indicate the safety and efficacy of Andexxa in reversing the anticoagulant drug of the factor Xa inhibitors rivaroxaban and apixaban in healthy volunteers. Further, the risk associated with anticoagulant drugs is a key driving factor of the market. Anticoagulant reversal drugs are used to reverse or neutralized the side effect of the anticoagulant drug. Some of the anticoagulant drugs include rivaroxaban, apixaban, dabigatran, warfarin, and more. Rivaroxaban and apixaban are anticoagulants used to reduce blood clotting and systemic embolism in patients with atrial fibrillation but can cause certain side effects including uncontrolled bleeding in the nose, bruise, blood in the urine, or bleeding gums. The incidence of bleeding side effects on rare occasions can be serious or even life-threatening. Andexxa is an antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis). Dabigatran (Pradaxa) is an anticoagulant drug, helps to reduce the risk of stroke in AFib.

Dabigatran’s major side effects can cause life-threatening and uncontrolled bleeding. Praxbind (idarucizumab) is a specific reversal agent for Pradaxa. Praxbind helps to reverse the anticoagulant effects for emergency surgical procedures or uncontrolled bleeding. However, the high cost of anticoagulant reversal drugs might hamper the market growth. Moreover, increasing clinical studies on anticoagulant reversal drugs would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global anticoagulant reversal drugs market is mainly classified based on type and application. Type is further segmented into Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa, and Others. By application, the market is divided into Hospital Pharmacies, Retail Pharmacies, and Others.

Vitamin K was dominating the global anticoagulant reversal drugs in 2019, owing to the partnership between companies to conduct clinical trials for anticoagulant reversal drugs commercialization of regulatory approved anticoagulant reversal drugs. For instance, Zydus Cadila has received the final approval from the U.S. Food and Drug Administration (FDA) to market Phytonadione Tablets USP (US RLD Mephyton), 5 mg. Phytonadione Tablets help in thickening of the blood and stop the bleeding. Phytonadione is vitamin K1 and helps to prevent low levels of blood clotting factors.

Regional Analysis

Based on geography, the global anticoagulant reversal drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global anticoagulant reversal drugs market in 2019, due to the increasing number of clinical studies for anticoagulant reversal drugs, the partnership between companies to collaboratively develop anticoagulant reversal drugs and regulatory approval for increasing large-scale commercial production of Andexxa. For instance, The U.S. Food and Drug Administration (FDA) has approved the Generation 2 manufacturing process for Andexxa. The Generation 2 manufacturing of Andexxa will enable to scale up production and stock hospitals nationwide. In 2017, approximately 140,000 hospital admissions attributable to Factor Xa inhibitor-related bleeding in the United States.

Competitive landscape

Key players operating in the anticoagulant reversal drugs industry include Bausch Health Companies, Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Amneal Pharmaceuticals, Inc., CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Cadila Healthcare, and Pfizer Inc.

The commercialization of regulatory approved anticoagulant reversal drugs, increasing clinical studies on anticoagulant reversal drugs, the collaboration between companies to develop reversal drugs, and strategic acquisition to expand the product portfolio with anticoagulant reversal drugs are some of the strategies adopted by the major companies. For instance, on January 17, 2019, AMAG Pharmaceuticals, Inc. has acquired Perosphere Pharmaceuticals Inc. to expand its development product portfolio by adds ciraparantag. Ciraparantag is in development statge as a single dose to treat patients with novel oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for life-threatening or uncontrolled bleeding.

Anticoagulant Reversal Drugs Market Key Segments

By Type
• Prothrombin Complex Concentrates (PCC)
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa
• Others

By Application
• Hospital Pharmacies
• Retail Pharmacies
• Others

Key Global Anticoagulant Reversal Drugs Industry Players

• Bausch Health Companies, Inc.
• Fresenius Kabi AG
• Amneal Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• CSL Limited
• Octapharma AG
• Portola Pharmaceuticals, Inc.
• Cadila Healthcare
• Pfizer Inc.

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Anticoagulant Reversal Drugs Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing Regulatory Approved for Anticoagulant Reversal Drugs
3.3.2. Risk Associated with Anticoagulant Drugs
3.4. Restraints
3.4.1. High Cost of Anticoagulant Reversal Drugs
3.5. Opportunity
3.5.1. Increasing Clinical Studies on Anticoagulant Reversal Drugs
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Prothrombin Complex Concentrates (PCC)
4.2.1. Market Size & Forecast
4.3. Vitamin K
4.3.1. Market Size & Forecast
4.4. Protamine
4.4.1. Market Size & Forecast
4.5. Tranexamic Acid
4.5.1. Market Size & Forecast
4.6. Idarucizumab
4.6.1. Market Size & Forecast
4.7. AndeXXa
4.7.1. Market Size & Forecast
4.8. Others
4.8.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hospital Pharmacies
5.2.1. Market Size & Forecast
5.3. Retail Pharmacies
5.3.1. Market Size & Forecast
5.4. Others
5.4.1. Market Size & Forecast

6. Anticoagulant Reversal Drugs Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Anticoagulant Reversal Drugs Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Anticoagulant Reversal Drugs Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Anticoagulant Reversal Drugs Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Anticoagulant Reversal Drugs Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Anticoagulant Reversal Drugs Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Bausch Health Companies, Inc.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Bausch Health Companies, Inc. Product Category, Application, and Specification
7.1.3. Bausch Health Companies, Inc. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Fresenius Kabi AG
7.3. Amneal Pharmaceuticals, Inc.
7.4. Boehringer Ingelheim GmbH
7.5. CSL Limited
7.6. Octapharma AG
7.7. Portola Pharmaceuticals, Inc.
7.8. Cadila Healthcare
7.9. Pfizer Inc.